Status:

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Lead Sponsor:

Shanghai Henlius Biotech

Conditions:

Limited-Stage Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ conc...

Detailed Description

Eligible subjects in this study will be randomized to Arm A or Arm B at 1:1 ratio. Arm A (Serplulimab arm): Serplulimab + chemotherapy(Carboplatin/Cisplatin-Etoposide)+concurrent radiotherapy; Arm B ...

Eligibility Criteria

Inclusion

  • Male or female, aged ≥18 years when signing the ICF.
  • Histologically diagnosed with SCLC.
  • Diagnosed with LS-SCLC (stage Ⅰ-Ⅲ of the AJCC 8th edition of the cancer staging), which can be safely treated with curative radiation doses.
  • Major organs are functioning well.

Exclusion

  • Histologically or cytologically confirmed mixed SCLC.
  • Subjects suitable for surgery. Subjects who are suitable for surgery but refuse surgical treatment can be included.
  • Patients who have previously received systematic anti-tumor treatments for small cell lung cancer, including but not limited to radiotherapy, chemotherapy, and immunotherapy.
  • Patients with other active malignancies within 5 years or at the same time.
  • Subjects with known history of severe allergy to any monoclonal antibody.
  • Subjects with known anaphylaxis to carboplatin/cisplatin or etoposide.
  • In the judgment of the investigator, subjects who have any other factors that may lead to a premature discontinuation.

Key Trial Info

Start Date :

May 17 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2026

Estimated Enrollment :

511 Patients enrolled

Trial Details

Trial ID

NCT05353257

Start Date

May 17 2022

End Date

December 30 2026

Last Update

January 28 2025

Active Locations (129)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 33 (129 locations)

1

OPN-Glendale

Arcadia, California, United States, 91007

2

OPN-Los Alamitos

Los Alamitos, California, United States, 90720

3

Southern California Permanente Group

Los Angeles, California, United States, 90034

4

Emad Ibrahim, MD, Inc

Redlands, California, United States, 92373